ASPERCREME LIDOCAINE FOOT (DIABETIC)- lidocaine hydrochloride cream 
Chattem, Inc.

----------

Aspercreme Lidocaine Foot Cream-Diabetic

ASPERCREME with LIDOCAINE FOOT PAIN CREAM

(For Diabetic Skin)

Drug Facts

Active ingredient

Lidocaine HCl 4%

Purpose

Topical anesthetic

Use

temporarily relieves minor pain

Warnings

For external use only 

Do not use

■ if you have serious foot problems, such as ulcers or infections 

■ if you have numbness or reduced ability to feel pain

■ on cut, irritated or swollen skin

■on puncture wounds

■ for more than one week without consulting a doctor

When using this product

use only as directed. Read and follow all directions and warning on this carton.

■ do not allow contact with the eyes and the mucous membranes

 do not bandage tightly or apply local heat (such as heating pads) or a medicated patch to the area of use

 do not use at the same time as other topical analgesics

Stop use and ask a doctor if

 condition worsens 

■ redness is present

■ irritation develops

■ symptoms persist for more than 7 days or clear up and occur again within a few days

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

Directions

adults and children over 12 years:

■ apply a thin layer to affected area every 6 to 8 hours, not to exceed 3 applications in a 24 hour period

■ massage into painful area until thoroughly absorbed into skin

        

children 12 years or younger: ask a doctor

Inactive ingredients

water, alcohol denat. (10%), cetearyl alcohol, ceteth-20 phosphate, dimethicone, caprylyl methicone, dicetyl phosphate, glyceryl stearate, aloe barbadensis leaf juice, panthenol, tocopheryl acetate, magnesium ascorbyl phosphate, aminomethyl propanol, C30-45 alkyl cetearyl dimethicone crosspolymer, acrylates/C10-30 alkyl acrylate crosspolymer, ethylhexylglycerin, methylparaben, disodium EDTA, citric acid

                                                                                   333-105

Child-resistant packaging. Close cap tightly after use.

PRINCIPAL DISPLAY PANEL

Max Strength
Aspercreme

Lidocaine

2 in 1

Pain Relief + Moisturization

foot cream

PRINCIPAL DISPLAY PANEL
Max Strength
Aspercreme
Lidocaine
2 in 1
Pain Relief + Moisturization
foot cream

ASPERCREME LIDOCAINE FOOT (DIABETIC) 
lidocaine hydrochloride cream
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:41167-0597
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987) LIDOCAINE HYDROCHLORIDE ANHYDROUS4 g  in 100 g
Inactive Ingredients
Ingredient NameStrength
WATER (UNII: 059QF0KO0R)  
ALCOHOL (UNII: 3K9958V90M)  
CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)  
CETETH-20 PHOSPHATE (UNII: 921FTA1500)  
DIMETHICONE (UNII: 92RU3N3Y1O)  
CAPRYLYL TRISILOXANE (UNII: Q95M2P1KJL)  
DIHEXADECYL PHOSPHATE (UNII: 2V6E5WN99N)  
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)  
ALOE VERA LEAF (UNII: ZY81Z83H0X)  
PANTHENOL (UNII: WV9CM0O67Z)  
.ALPHA.-TOCOPHEROL ACETATE (UNII: 9E8X80D2L0)  
MAGNESIUM ASCORBYL PHOSPHATE (UNII: 0R822556M5)  
AMINOMETHYLPROPANOL (UNII: LU49E6626Q)  
C30-45 ALKYL CETEARYL DIMETHICONE CROSSPOLYMER (UNII: 4ZK9VP326R)  
ETHYLHEXYLGLYCERIN (UNII: 147D247K3P)  
METHYLPARABEN (UNII: A2I8C7HI9T)  
EDETATE DISODIUM ANHYDROUS (UNII: 8NLQ36F6MM)  
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
CARBOMER INTERPOLYMER TYPE A (ALLYL SUCROSE CROSSLINKED) (UNII: 59TL3WG5CO)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:41167-0597-01 in 1 CARTON06/01/2018
1113 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC Monograph DrugM01706/01/2018
Labeler - Chattem, Inc. (003336013)

Revised: 10/2023
Document Id: ddbc8249-6deb-4d72-8576-38e8a7bfba23
Set id: 2c33d15e-5032-46d9-bd98-5abc7df3bbe5
Version: 3
Effective Time: 20231023
 
Chattem, Inc.